Aging & mental health · 2025
Repetitive transcranial magnetic stimulation: an effective treatment for resistant depressive episodes in the elderly.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Harika-Germaneau Ghina, Wassouf Issa, Doolub Damien, Delbreil Alexia, Vassort Louis, Chavanel David, Jaafari Nematollah
Аннотация
OBJECTIVES: To evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in older (≥60 years) versus younger (<60 years) patients with treatment-resistant depression (TRD), and to determine whether age affects clinical outcomes in a naturalistic clinical setting.
METHOD: A retrospective analysis was conducted on 272 patients with TRD treated with rTMS at a tertiary psychiatric hospital. Depression severity was assessed at baseline, end-of-treatment (V1), and one-month follow-up (V2) using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory (BDI). Response (≥50% MADRS reduction) and remission (MADRS ≤10) rates were calculated. Repeated measures ANOVA and logistic regression were used to examine the influence of age and treatment protocol.
RESULTS: Both age groups showed significant improvement in depressive symptoms. Older adults had higher remission rates at V1 (36% vs. 23%, p = 0.033), although this difference was no longer significant at V2. No interaction between age and protocol was observed. Female sex was the only significant predictor of remission at V2 (OR = 14.25, p = 0.021). Sensitivity analyses treating age as a continuous variable yielded consistent findings.
CONCLUSION: rTMS is an effective treatment for TRD in both older and younger adults. Older patients respond comparably to younger ones, challenging concerns about age-related reductions in neuromodulation efficacy. These findings support the use of rTMS in late-life depression without major protocol adjustments and underscore the need for future studies examining personalized treatment parameters and psychosocial moderators of response.
METHOD: A retrospective analysis was conducted on 272 patients with TRD treated with rTMS at a tertiary psychiatric hospital. Depression severity was assessed at baseline, end-of-treatment (V1), and one-month follow-up (V2) using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory (BDI). Response (≥50% MADRS reduction) and remission (MADRS ≤10) rates were calculated. Repeated measures ANOVA and logistic regression were used to examine the influence of age and treatment protocol.
RESULTS: Both age groups showed significant improvement in depressive symptoms. Older adults had higher remission rates at V1 (36% vs. 23%, p = 0.033), although this difference was no longer significant at V2. No interaction between age and protocol was observed. Female sex was the only significant predictor of remission at V2 (OR = 14.25, p = 0.021). Sensitivity analyses treating age as a continuous variable yielded consistent findings.
CONCLUSION: rTMS is an effective treatment for TRD in both older and younger adults. Older patients respond comparably to younger ones, challenging concerns about age-related reductions in neuromodulation efficacy. These findings support the use of rTMS in late-life depression without major protocol adjustments and underscore the need for future studies examining personalized treatment parameters and psychosocial moderators of response.